On the question of the antiproliferative coating of coronary stents

The article looks at the issue of antiproliferative coatings of drug eluting coronary stents from a perspective of their pharmacological properties. Antiproliferative drugs from the “limus” group used in coronary stents do not have decisive advantages over each other. This statement is based on the same pharmacological nature of drugs of the rapamycin group. Regardless of the technology of their creation and the indications for medical use, these drugs have absolutely the same mechanism of pharmacological effects. Currently, all available preparations from the "limus" group satisfy the required pharmacodynamic parameters to achieve a delayed clinical effect in coronary stenting. The coronary stent classification supposes their ranking only by the platform and the eluting system, without taking into account the type of antiproliferative drugs.